Dr. John Matthew Timmerman, MD

Dr. Timmerman practices at UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health.

Dr. Timmerman's NPI, 1891715090, was assigned on July 20, 2006. Dr. Timmerman graduated from Boston University School of Medicine in 1991. Dr. Timmerman holds California license G76297.

Dr. Timmerman's primary practice is UCLA Santa Monica Medical Center, at 1250 16th Street, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 319-4000.

Dr. Timmerman's primary practice is UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health. Dr. Timmerman is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Timmerman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Timmerman practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Timmerman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Timmerman is licensed in California.

CMS data shows 624 Medicare services from Dr. Timmerman across 9 procedure codes in 2024, for 156 Medicare patients. Medicare paid $49,063 for them.

CMS counts 156 Medicare patients who saw Dr. Timmerman in 2024. The largest group is 65 to 74, with 79 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Timmerman's median patient age at 64, with 45% women.

In 2024, Dr. Timmerman wrote 54 Medicare Part D claims for 13 patients. 31% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $288,095 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Timmerman for performance year 2024, reported as part of a group. Dr. Timmerman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Timmerman as offering telehealth.

Dmand AI links 41 papers to Dr. Timmerman, published from 2009 to 2024. 2019 was the busiest year, with 5. The most frequent topics are Immunotherapy, Adoptive, Biological Products and Lymphoma, Large B-Cell, Diffuse. Dr. Timmerman has published most often in Clin Cancer Res. Dr. Timmerman's most frequent co-authors are Philippe Armand, MD, PhD, Caron Alyce Jacobson, MD and Andre H. Goy, MD.

Dmand AI links Dr. Timmerman to 7 clinical trials, 4 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Lymphoma, Non-Hodgkin, Lymphoma and Disease Attributes. Kite, A Gilead Company sponsors the most, 2.

CMS Open Payments shows 69 general payments to Dr. Timmerman from 10 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 89% of the total. Kite Pharma, Inc. paid the most, $15,166.

Dr. Timmerman graduated from Boston University School of Medicine in 1991.